化瘀消癥方联合米非司酮治疗围绝经期子宫腺肌病的临床视察.pdfVIP

提 要 目的：观察化瘀消癥方联合米非司酮治疗围绝经期子宫腺肌病的临床疗效，并初 步探讨其作用机制。方法：将 60例围绝经期子宫腺肌病患者随机分为治疗组（30例， 口服化瘀消癥方及米非司酮）和对照组（30例，口服米非司酮），观察两组患者治疗 前后临床症状与体征的改善情况，以及两组患者的血红蛋白、免疫学指标、血液流变 学、女性内分泌激素的变化情况。结果：治疗组临床疗效及中医症候疗效优于对照组, 比较有显著性差异(P0.05)；治疗组在缩小宫体、纠正贫血、改善各项实验室指标方 面疗效显著 (P0.05)；经随访观察治疗组在诱导绝经及缩小宫体的疗效稳定性方面 优于对照组，有显著性差异(PO.05)。结论：化瘀消癥方联合米非司酮能改善临床症 状和体征，缩小宫体，纠正贫血，改善血液流变学及女性内分泌水平，并能诱导绝经， 增强机体免疫力，对围绝经期子宫腺肌病有较好的临床疗效。 关键词 化瘀消癥方；米非司酮；围绝经期；子宫腺肌病；临床疗效 The clinical efficacy of treating menopause adenomyosis with the Circulation Xiaozheng combined with mifepristone Speciality： Gynecology of TCM Tutor： LvMei Author ： DongSixia Abstract Objective: To observe the clinical efficacy of the circulation Xiaozheng side combined with mifepristone in treating confining postmenopausal adenomyosis, and to explore its mechanism of action. Method: 60 cases of perimenopausal adenomyosis patients are randomly divided into treatment group (30 cases, oral circulation Xiaozheng side and mifepristone) and the control group (30 cases, oral mifepristone). Observe the clinical symptoms and signs of the patients of two groups before and after the treatment, as well as the changes of hemoglobin, immunological parameters, blood rheology, and the female endocrine hormone of the patients of two groups. Results: The clinical efficacy of the treatment group, namely, the efficacy of Chinese medicine symptomatology is better than the control group, and the statistical result is significant difference (P0.05); treatment group is significant in the efficacy of narrow Palace, correct anemia, improve various laboratory parameters (P0.05); follow-up observation and treatment group are better than the control group in the induction of menopause and reduce the efficacy of the Palace o